Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Good Therapeutics is raising $22,335,003.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John Mulligan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Good Therapeutics

Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing context-dependent protein drugs that sense biomarkers and respond with a therapeutic activity. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Our core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. We are currently focused on immuno-oncology applications of the technology.

To learn more about Good Therapeutics, visit http://www.goodtherapeutics.com/

Contact:
John Mulligan, Chief Executive Officer
425-591-9641
mulligan@goodtherapeutics.com
https://www.linkedin.com/in/john-mulligan-ph-d-5aa5a37/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved